ArticleCureus2025
Linear IgA Bullous Dermatosis in an Elderly Patient Following Meloxicam and Candesartan Use: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linear immunoglobulin A (IgA) bullous dermatosis (LABD) is a rare autoimmune blistering disorder characterized by subepidermal blisters and linear IgA deposition along the dermo-epidermal junction (DEJ). We report the case of a 61-year-old woman who developed multiple tense vesicles and bullae on an erythematous base affecting both upper and lower extremities after initiating meloxicam for postoperative analgesia following knee arthroplasty. A punch biopsy showed subepidermal blistering, while direct immunofluorescence demonstrated linear IgA deposition along the basement membrane zone, confirming LABD. After discontinuation of the suspected culprit drug and adjustment of her antihypertensive therapy, she was treated with oral dapsone 1 mg/kg (50 mg) daily for two weeks, resulting in clinical improvement. This case underscores the importance of thorough drug history taking and early recognition of drug-induced LABD, particularly in patients on multiple medications, where identifying the true offending agent may be challenging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.